Principal Financial Group
TSHA icon

Principal Financial Group’s Taysha Gene Therapies TSHA Stock Holding History

Principal Financial Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125K Buy
18,334
+2,149
+13% +$12.7K ﹤0.01% 2106
2026
Q1 		$72.3K Buy
16,185
+3,362
+26% +$15.6K ﹤0.01% 2134
2025
Q4 		$70.5K Sell
12,823
-3,428
-21% -$16.6K ﹤0.01% 2156
2025
Q3 		$53.1K Buy
16,251
+4,091
+34% +$11.6K ﹤0.01% 2212
2025
Q2 		$28.1K Sell
12,160
-1,829
-13% -$3.97K ﹤0.01% 2205
2025
Q1 		$19.4K Sell
13,989
-982
-7% -$1.64K ﹤0.01% 2148
2024
Q4 		$25.9K Sell
14,971
-828
-5% -$1.72K ﹤0.01% 2192
2024
Q3 		$31.8K Sell
15,799
-5,810
-27% -$12.7K ﹤0.01% 2196
2024
Q2 		$48.4K Buy
+21,609
New +$62.9K ﹤0.01% 2287

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Principal Financial Group's TSHA Position: Q2 2026 in Review

Principal Financial Group increased its Taysha Gene Therapies (TSHA) stake by 13% in Q2 2026, buying an estimated $12.7K and bringing the position to 18,334 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #2106.

Principal Financial Group first reported a position in TSHA in Q2 2024 and has held it in 9 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Principal Financial Group held 18,334 shares of Taysha Gene Therapies worth $125K as of Q2 2026.
  • Principal Financial Group bought 2,149 Taysha Gene Therapies shares in Q2 2026, an estimated $12.7K.
  • Taysha Gene Therapies made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #2106 holding.
  • Principal Financial Group first reported a position in Taysha Gene Therapies in Q2 2024 and has held it in 9 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.